Celebrating Mental Health Champions: Cypress Project Instructors Make History

Neural Therapeutics Aims to Finalize Acquisition of CWE: Key Details Ahead of Shareholder Meeting

Update Neural Therapeutics Pushes Forward with Key Acquisition Plans On May 1, 2026, Neural Therapeutics Inc. announced the filing and mailing of materials associated with its upcoming annual and special meeting, slated for May 25, 2026. Here, shareholders will review and vote on significant proposals, including a proposed acquisition of the remaining 69.25% interest it does not currently own in CWE European Holdings Inc. (CWE), a company noted for its focus on the booming CBD market under the brand Hanf.com. This acquisition could mark a pivotal shift for Neural Therapeutics, enabling complete ownership of CWE and enhancing its presence in the burgeoning European markets for cannabis and ethnobotanical medicines. The Significance of CWE Acquisition The intent to acquire CWE aligns with Neural's broader strategy to transform its operations from purely research and development towards commercial viability. As outlined in previous press releases, this acquisition represents an important step for Neural in establishing a strong foothold in Germany’s regulated CBD market. CWE has built a reputable brand in this space, capitalizing on the growing demand for CBD products. With this acquisition, Neural Therapeutics would not only expand its market reach but also integrate its innovative drug discovery capabilities with CWE’s established retail operations. What’s on the Agenda During the upcoming shareholder meeting, stakeholders will vote on several critical matters: The acquisition of CWE, which will consolidate Neural’s interests and create a stronger, unified commercial entity. A proposed consolidation of the company’s common shares at a ratio of one post-consolidation share for every four pre-consolidation shares, which could enhance shareholder value. The potential rebranding to Hanf.com Inc., aligning the company’s identity more closely with its flagship subsidiary. The usual business of electing board members, appointing auditors, and ratifying incentive plans. The company’s board recommends that shareholders vote in favor of these proposals, underscoring their belief in the strategic merits of the plans being set forth. Webcast Participation for Shareholders For shareholders unable to attend in-person, Neural has arranged a live audio webcast of the meeting, ensuring that all voices can be heard, even if not physically present. While voting will not be possible via the webcast, shareholders will have the opportunity to ask questions after the meeting. This digital approach reflects a trend towards greater inclusivity in corporate governance. Financial and Regulatory Considerations The Series B Transactions, as they are termed, involve not only the acquisition of CWE but also navigating various regulatory channels, including obtaining approvals from the Canadian Securities Exchange (CSE). The proposed changes, particularly the share consolidation and acquisition, will need to adhere to regulations designed to protect shareholder interests. The completion of these transactions will represent a fundamental change in Neural’s structure, hence the rigor surrounding the approvals. Moreover, in conjunction with the acquisition, CWE plans to initiate a private financing round, indicating a proactive approach to capitalize on upcoming opportunities. The Future of Neural Therapeutics If approved, the Series B Transactions could signify a transformative phase for Neural Therapeutics. The full integration of CWE would afford Neural a direct line to retail operations in Europe, potentially leading to enhanced revenue streams. As indicated by statements from Neural’s leadership, this transaction stands as a critical pivot from a research-focused entity to an operational powerhouse poised for growth within the pharmaceutical and wellness sectors. Why Shareholder Engagement Matters The call for shareholder engagement is underscored in the company’s communications; every vote counts, regardless of the number of shares held. By encouraging early participation in the voting process, Neural aims to ensure that the voice of every shareholder is heard and accounted for. This engagement not only supports corporate accountability but also fosters a deeper connection between the company’s strategic path and its investors. In summary, the upcoming shareholder meeting and the proposed Series B Transactions represent a crucial chapter in Neural Therapeutics’ journey. With a clear vision towards integrating and expanding its operations through CWE, the company is strategically positioned to leverage the evolving landscape of the health and wellness market. Neural’s commitment to transparency and stakeholder involvement serves as a model for corporate governance within an industry poised for rapid growth.